The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody

Infection and Immunity

Volumn 67, Issue 9, 1999, Pages 4620-4627

  Syme, Rachel M ^a   Bruno, Tony F ^a   Kozel, Thomas R ^b   Mody, Christopher H ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSULAR POLYSACCHARIDE; INTERLEUKIN 10; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; VIRULENCE;

EID: 0032810567     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.9.4620-4627.1999     Document Type: Article

References (51)

1. Aguirre, K., E. A. Havell, G. W. Gibson, and L. L. Johnson. 1995. Role of tumor necrosis factor and gamma Interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect. Immun. 63:1725-1731.
2. Blasi, E., R. Barluzzi, R. Mazzolla, L. Pitzurra, M. Puliti, S. Saleppico, and F. Bistoni. 1995. Biomolecular events involved in anticryptococcal resistance in the brain. Infect. Immun. 63:1218-1222.
3. Chaka, W., J. Scharringa, A. F. Verheul, J. Verhoef, A. G. Van Strijp, and I. M. Hoepelman. 1995. Quantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry. Clin. Lab. Immunol. 2:753-759.
4. Coker, R. J. 1992. Cryptococcal infection in AIDS. Int. J. Sex. Transm. Dis. AIDS 3:168-172.
5. Collins, H. L., and G. J. Bancroft. 1991. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect. Immun. 59: 3883-3888.
6. Das, K. C., and H. P. Misra. 1994. Impairment of RAW 264.7 macrophage function by antiarrhythmic drugs. Mol. Cell. Biochem. 132:151-162.
7. Davies, S. R., D. P. Clifford, J. R. Hoidal, and J. E. Repine. 1982. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J. Infect. Dis. 145:870-874.
8. Del Prete, G., M. De Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150:353-360.
9. Deshaw, M., and L. A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV-individuals. Clin. Exp. Immunol. 99:425-432.
10. Devi, S. J. 1996. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841-844.
11. Devi, S. G. N., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700-3707.
12. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocyte: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174: 1209-1220.
13. Dismukes, W. E. 1988. Cryptococcal meningitis in patients with AIDS. J. Infect. Dis. 157:624-628.
14. Dong, Z. M., and J. W. Murphy. 1996. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J. Clin. Invest. 97:689-698.
15. Dromer, J., C. Perronne, J. Barge, J. L. Vilde, and P. Yeni. 1989. Role of IgG and the complement component C5 in the initial course of experimental cryptococcosis. Clin. Exp. Immunol. 78:412-417.
16. Eckert, T. F., and T. R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:1895-1899.
17. Feldmesser, M., and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol. 158:790-799.
18. Grant, I. H., and D. Armstrong. 1988. Fungal infections in AIDS. Ctyptococcosis. Infect. Dis. Clin. N. Am. 2:457-464.
19. Houpt, D. C., G. S. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immnoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:2857-2864.
20. Huffnagle, G. B., G. B. Toews, M. D. Burdick, M. B. Boyd, K. S. McAllister, R. A. McDonald, S. L. Kunkel, and R. M. Strieter. 1996. Afferent phase production of TNF-α is required for development of protective T cell immunity to Cryptococcus neoformans. J. Immunol. 157:4529-4536.
21. Jacobson, E. S., D. J. Ayers, A. C. Harrell, and C. C. Nicholas. 1982. Genetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans. J. Bacteriol. 150:1292-1296.
22. Kozel, T. R., and C. A. Hermerath. 1984. Binding of cryptococcal polysaccharide to Cryptococcus neoformans. Infect. Immun. 43:879-886.
23. Kozel, T. R. 1977. Nonencapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect. Immun. 16:99-106.
24. Kozel, T. R., and J. Cazin. 1971. Nonencapsulated variant of Cryptococcus neoformans. I. Virulence studies of characterization of soluble polysaccharide. Infect. Immun. 3:287-294.
25. Kozel, T. R., and R. P. Mastrolanni. 1976. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis. Infect. Immun. 14:62-67.
26. Kozel, T. R., and T. G. McGaw. 1979. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect. Immun. 25:255-261.
27. Kozel, T. R., G. S. T. Pfrommer, A. S. Guerlain, B. A. Highison, and G. J. Highison. 1988. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3. Infect. Immun. 56:2794-2800.
28. Levitz, S. M., and D. J. DiBenedetto. 1988. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Infect. Immun. 56:2544-2551.
29. Levitz, S. M., and T. P. Fanrell. 1990. Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule opsonins, the culture surface, and cytokines. Infect. Immun. 58:1201-1209.
30. Levitz, S. M., T. P. Farrell, and R. T. Maziarz. 1991. Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. J. Infect. Dis. 163:1108-1113.
31. Levitz, S. M., and A. Tabuni. 1991. Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. J. Clin. Invest. 87:528-535.
32. Mitchell, T. G., and L. Friedman. 1972. In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans. Infect. Immun. 5:491-498.
33. Mody, C. H., and R. M. Syme. 1993. Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect. Immun. 61:464-469.
34. Mody, C. H., G, B. Toews, and M. F. Lipscomb. 1988. Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model. Infect. Immun. 56:7-12.
35. Monari, C., C. Retini, B. Palazzetti, F. Bistoni, and A. Vecchiarelli. 1997. Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clin. Exp. Immunol. 109:242-247.
36. Mukherjee, J., G. Nussbaum, M. D. Scharff, and A. Casadevall. 1995. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J. Exp. Med. 181:405-409.
37. Muhherjee, J., L. S. Zuckier, M. D. Scharff, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38:580-587.
38. Mukherjee, S., S. C. Lee, and A. Casadevall. 1994. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
39. Pirofski, L., R. Lui, M. DeShaw, A. B. Kressel, and Z. Zhong. 1995. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63-.3005-3014.
40. Retini, C., A. Vecchiarelli, C. Monari, F. Bistoni, and T. R. Kozel. 1998. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun. 66:664-669.
41. Small, J. M., T. G. Mitchell, and R. W. Wheat. 1986. Strain variation in composition and molecular size of the capsular polysaccharide of Cryptococcus neoformans serotype A. Infect. Immun. 54:735-741.
42. Spiropulu, C., R. A. Eppard, E. Otteson, and T. R. Kozel. 1989. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect. Immun. 57: 3240-3242.
43. Vecchiarelli, A., D. Pietrella, M. Dottorini, C. Monari, C. Retini, T. Todisco, and F. Bistoni. 1994. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98:217-223.
44. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1β secretion from human monocytes. Infect. Immun. 63:2919-2923.
45. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64:2846-2849.
46. Vecchiarelli, A., C. Retini, C. Monari, and A. Casadevall. 1998. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation. Infect. Immun. 64:1244-1247.
47. Wilson, D. E., J. E. Bennett, and J. W. Bailey. 1968. Serologic grouping of Cryptococcus neofomans. Proc. Soc. Exp. Biol. Med. 127:820-823.
48. Young, B. J., and T. R. Kozel. 1993. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61:2966-2972.
49. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J. Immunol. 154:1810-1816.
50. Yuan, R., A. Casadevall, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94:2483-2488.
51. Zhong, Z., and L. Pirofski. 1996. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect. Immun. 64:3446-3450.